Related Experiment Video

Updated: Feb 18, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

First Approved Kinase Inhibitor for AML

John E J Rasko1, Timothy P Hughes2

  • 1Centenary Institute, University of Sydney and Cell & Molecular Therapies at Royal Prince Alfred Hospital, Australia.

Cell
|November 18, 2017
PubMed

Insights

Activating mutations in FLT3 are common in acute myeloid leukemia (AML) and linked to poor outcomes. Midostaurin, a multi-kinase inhibitor, is a new treatment option for FLT3-mutated AML.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are found in approximately 30% of acute myeloid leukemia (AML) cases.
  • These FLT3 mutations are associated with a higher risk of relapse and poorer prognosis in AML patients.

Purpose of the Study:

  • To highlight the significance of FLT3 mutations in AML.
  • To introduce Midostaurin as a novel therapeutic agent for FLT3-mutant AML.

Main Methods:

  • Review of clinical data and therapeutic approvals.
  • Discussion of Midostaurin's mechanism as a multi-kinase inhibitor.

Main Results:

  • Midostaurin represents the first drug approved for AML since 2000.
  • Midostaurin is the first approved multi-kinase inhibitor specifically for the FLT3-mutant subtype of AML.

Conclusions:

  • Midostaurin offers a targeted treatment approach for a significant subset of AML patients.
  • The approval of Midostaurin marks a significant advancement in AML therapy.

More Related Videos

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

980
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

829

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
22